Author: "Vaiva, Guillaume" / Database: OpenAIRE - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Vaiva, Guillaume"' showing total 36 results

Start Over Author "Vaiva, Guillaume" Database OpenAIRE

36 results on '"Vaiva, Guillaume"'

1. Diurnal symptoms of sleepiness and dysfunction predict future suicidal ideation in a French cohort of outpatients (FACE-DR) with treatment resistant depression: A 1-year prospective study about sleep markers

Author: Maruani, Julia, Molière, Fanny, Godin, Ophelia, Yrondi, Antoine, Bennabi, Djamila, Richieri, Raphaelle, El-Hage, Wissan, Allauze, Etienne, Anguill, Loic, Bouvard, Alexandra, Camus, Vincent, Dorey, Jean-Michel, Etain, Bruno, Fond, Guillaume, Genty, Jean-Baptiste, Haffen, Emmanuel, Holtzmann, Jérôme, Horn, Mathilde, Kazour, François, Nguon, Anne-Sophie, Petrucci, Jean, Rey, Romain, Stephan, Florian, Vaiva, Guillaume, Walter, Michel, Lejoyeux, Michel, Leboyer, Marion, Llorca, Pierre-Michel, Courtet, Philippe, Aouizerate, Bruno, Geoffroy, Pierre, Fondation FondaMental [Créteil], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut FRESNEL (FRESNEL), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), UMR 1253 IBrain Imagerie & Cerveau Equipe 1 : 'Psychiatrie Neuro-Fonctionnelle' (PNF), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Nutrition et Neurobiologie intégrée (NutriNeuro), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre hospitalier Charles Perrens [Bordeaux], Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier le Vinatier [Bron], Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), [GIN] Grenoble Institut des Neurosciences (GIN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), CHU Lille, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital de Bohars - CHRU Brest (CHU - BREST ), Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale (EA7479 SPURBO), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), GHU Paris Psychiatrie et Neurosciences, Maladies neurodéveloppementales et neurovasculaires (NeuroDiderot (UMR_S_1141 / U1141)), and FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) Collaborators
Subjects: MESH: Humans, MESH: Suicidal Ideation, MESH: Sleepiness, MESH: Sleep, Excessive daytime sleepiness, Circadian, MESH: Depressive Disorder, Major, Daytime dysfunction, MESH: Prospective Studies, MESH: Outpatients, MESH: Depressive Disorder, Treatment-Resistant, Psychiatry and Mental health, Clinical Psychology, MESH: Risk Factors, Suicidal ideation, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Treatment-resistant depression, Sleep
Abstract: International audience; Background: Patients suffering from treatment-resistant depression (TRD) are at risk of suicide. Sleep and circadian rhythm alterations are widely recognized as core symptoms of major depressive disorder and are associated with suicidal ideation. Thus, sleep and circadian rhythm alterations may be targeted to prevent suicide.Methods: Patients were recruited from a prospective cohort of the French network of TRD expert centers. Mood, sleep and circadian rhythms were assessed at baseline; suicidal risk was assessed both at baseline and during a one-year follow-up with standardized subjective questionnaires.Results: Excessive daytime sleepiness (adjusted odds ratio aOR = 1.7(1-3.3), p = 0.04) and daytime dysfunction (aOR = 1.81(1.16-2.81), p = 0.0085) increased the risk of suicidal thoughts over the one-year follow-up period in patients with TRD after adjustment on age, gender, depression, trauma, anxiety, impulsivity, current daily tobacco smoking and body mass index. Hypnotics intake is associated with a reduced risk of suicidal ideation at one-year follow-up after the same adjustments (OR = 0.73(0.56-0.95), p = 0.019). Other associations between sleep quality or circadian rhythms and suicidal ideations at either baseline or one year did not remain significant in multivariate analyses after the same adjustments.Limitations: Sleep assessments were based on self-reported questionnaires rather than objective measures.Conclusions: Daytime sleepiness and dysfunction are predictors of suicidal ideations, whereas hypnotics intake is associated with a reduced risk of suicidal ideations. Diurnal symptoms of sleep disturbances are therefore red flags to target for preventing suicide in depressed patients, and hypnotics seem efficient in preventing suicide for patients with TRD.
Published: 2023

2. sj-pdf-1-jgp-10.1177_08919887221149142 – Supplemental Material for Assessment of a Suicide Prevention Gatekeeper Training Program for Nursing Home Staff

Author: Demesmaeker, Alice, Baelde, Nicolas, Amad, Ali, Roche, Jean, Playe, Marie, Vaiva, Guillaume, Amariei, Alina, Blervaque, Wanda, Defebvre, Marguerite Marie, Caron, Brigitte, Puisieux, Francois, and Plancke, Laurent
Subjects: FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110308 Geriatrics and Gerontology, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract: Supplemental Material, sj-pdf-1-jgp-10.1177_08919887221149142 for Assessment of a Suicide Prevention Gatekeeper Training Program for Nursing Home Staff by Alice Demesmaeker, Nicolas Baelde, Ali Amad, Jean Roche, Marie Playe, Guillaume Vaiva, Alina Amariei, Wanda Blervaque, Marguerite Marie Defebvre, Brigitte Caron, Francois Puisieux and Laurent Plancke in Journal of Geriatric Psychiatry and Neurology
Published: 2023
Full Text: View/download PDF

3. sj-pdf-1-jgp-10.1177_08919887221149142 – Supplemental Material for Assessment of a Suicide Prevention Gatekeeper Training Program for Nursing Home Staff

Author: Demesmaeker, Alice, Baelde, Nicolas, Amad, Ali, Roche, Jean, Playe, Marie, Vaiva, Guillaume, Amariei, Alina, Blervaque, Wanda, Defebvre, Marguerite Marie, Caron, Brigitte, Puisieux, Francois, and Plancke, Laurent
Subjects: FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110308 Geriatrics and Gerontology, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract: Supplemental Material, sj-pdf-1-jgp-10.1177_08919887221149142 for Assessment of a Suicide Prevention Gatekeeper Training Program for Nursing Home Staff by Alice Demesmaeker, Nicolas Baelde, Ali Amad, Jean Roche, Marie Playe, Guillaume Vaiva, Alina Amariei, Wanda Blervaque, Marguerite Marie Defebvre, Brigitte Caron, Francois Puisieux and Laurent Plancke in Journal of Geriatric Psychiatry and Neurology
Published: 2023
Full Text: View/download PDF

4. Acceptability and satisfaction with emma, a smartphone application dedicated to suicide ecological assessment and prevention

Author: Morgiève, Margot, Yasri, Daniel, Genty, Catherine, Dubois, Jonathan, Leboyer, Marion, Vaiva, Guillaume, Berrouiguet, Sofian, Azé, Jérôme, Courtet, Philippe, CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Lapeyronie [Montpellier] (CHU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Fondation FondaMental [Créteil], Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre National de Ressources et de Résilience [Lille] (CN2R), CHRU Brest - Psychiatrie Adulte (CHU - Brest- Psychiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire de Traitement de l'Information Medicale (LaTIM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), ADVanced Analytics for data SciencE (ADVANSE), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier (LIRMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génomique Fonctionnelle (IGF), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
Subjects: Psychiatry and Mental health, mHealth, prevention, acceptability, ecological momentary assessment (EMA), satisfaction, ecological momentary intervention (EMI), smartphone application, suicide, [SHS]Humanities and Social Sciences
Abstract: BackgroundAs mHealth may contribute to suicide prevention, we developed emma, an application using Ecological Momentary Assessment and Intervention (EMA/EMI).ObjectiveThis study evaluated emma usage rate and acceptability during the first month and satisfaction after 1 and 6 months of use.MethodsNinety-nine patients at high risk of suicide used emma for 6 months. The acceptability and usage rate of the EMA and EMI modules were monitored during the first month. Satisfaction was assessed by questions in the monthly EMA (Likert scale from 0 to 10) and the Mobile App Rating Scale (MARS; score: 0–5) completed at month 6. After inclusion, three follow-up visits (months 1, 3, and 6) took place.ResultsSeventy-five patients completed at least one of the proposed EMAs. Completion rates were lower for the daily than weekly EMAs (60 and 82%, respectively). The daily completion rates varied according to the question position in the questionnaire (lower for the last questions, LRT = 604.26, df = 1, p-value < 0.0001). Completion rates for the daily EMA were higher in patients with suicidal ideation and/or depression than in those without. The most used EMI was the emergency call module (n = 12). Many users said that they would recommend this application (mean satisfaction score of 6.92 ± 2.78) and the MARS score at month 6 was relatively high (overall rating: 3.3 ± 0.87).ConclusionEmma can target and involve patients at high risk of suicide. Given the promising users’ satisfaction level, emma could rapidly evolve into a complementary tool for suicide prevention.
Published: 2022

5. The PRINTEMPS study: protocol of a cluster-randomized controlled trial of the local promotion of a smartphone application and associated website for the prevention of suicidal behaviors in the adult general population in France

Author: Gandré, Coralie, Le Jeannic, Anaïs, Vinet, Marie-Amélie, Turmaine, Kathleen, Courtet, Philippe, Roelandt, Jean-Luc, Vaiva, Guillaume, Giraudeau, Bruno, Alberti, Corinne, Chevreul, Karine, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), and Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Subjects: Adult, Male, Suicide Prevention, Cost-Benefit Analysis, [SDV]Life Sciences [q-bio], Intervention, Health Promotion, Psychological distress, Help-seeking, Study Protocol, Cluster Analysis, Humans, Promotion, Randomized Controlled Trials as Topic, lcsh:R5-920, E-health, Prevention, Local authorities, General population, Mobile Applications, Telemedicine, ArtThese, Suicide, Female, Mental health, France, Smartphone, lcsh:Medicine (General), Follow-Up Studies, Program Evaluation
Abstract: International audience; BACKGROUND: Suicide constitutes a cause of death which could be prevented by e-health programs accessible to the general population. Effective promotion has the potential to maximize the uptake of such programs. However, few e-health programs have been combined with promotion campaigns. The primary objective of this trial is to assess the effectiveness of a tailored promotion, at a local level, of a mobile application and website offering evidence-based content for suicide prevention (the StopBlues program), and to compare the effectiveness of two types of local promotion in terms of their impact on suicidal acts. Secondary objectives focus on the effectiveness of the promotion in terms of the intensity of utilization of the StopBlues program, help-seeking behaviors and the level of psychological impairment of program users. METHODS/DESIGN: This is a three-arm, parallel-group, cluster-randomized controlled trial, with before-and-after observation. Thirty-four clusters, corresponding to geographical areas sharing a common local authority in France, will be included. They will be randomly assigned to one of the following arms with a ratio of 1:1:1: a control group; a basic promotion group in which promotion of the StopBlues program will be done by local authorities; and an intensified promotion group in which basic promotion will be supplemented by an additional one in a general practitioner's waiting room. The primary outcome measure will be the number of suicidal acts within each cluster over a 12-month period following the launch of the intervention. Baseline data will be collected for each cluster over the 12-month period prior to the trial. Secondary outcomes will include length of use of the StopBlues program, measures of help-seeking behaviors and level of psychological distress among users of the program, as well as the cost-effectiveness and budgetary impact of its promotion. A more sustained promotion by local authorities will also be implemented after 12\,months in the control group and assessed using the same outcome measures. DISCUSSION: This research should contribute to the sparse evidence base regarding the promotion of e-health programs and will support the wider delivery of the intervention evaluated if proven effective. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03565562. Registered on 11 June 2018.
Published: 2020

6. Incidence of PTSD in the French population a month after the COVID-19 pandemic-related lockdown: evidence from a national longitudinal survey

Author: Alleaume, Caroline, Peretti-Watel, Patrick, Beck, François, Leger, Damien, Vaiva, Guillaume, Verger, Pierre, Raude, Jocelyn, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Sommeil-Vigilance-Fatigue et Santé Publique (VIFASOM (URP_7330)), Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Université Paris Cité (UPCité), Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), École des Hautes Études en Santé Publique [EHESP] (EHESP), The COCONEL Group, Centre de recherche en économie et management (CREM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)- Southeastern Health Regional Observatory (ORS Paca)-Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, ANR-20-COVI-0035-01, COCONEL Group: Patrick Peretti-Watel, Valérie Seror, Sébastien Cortaredona, Odile Launay, Jocelyn Raude, Pierre Verger, Caroline Alleaume, Lisa Fressard, Guillaume Vaiva, François Beck, Stéphane Legleye, Damien Léger, Olivier L'Haridon, Jeremy K Ward, ANR-20-COVI-0035,COCONEL,COronavirus et CONfinement : Enquête Longitudinale(2020), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Institut de Recherche Biomédicale des Armées (IRBA)-Université Paris Cité (UPCité), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), and EHESP, SCD
Subjects: [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Adult, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Depression, Incidence, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Public Health, Environmental and Occupational Health, PTSD, Anxiety, PCL-5, Stress Disorders, Post-Traumatic, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Communicable Disease Control, Lockdown, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Longitudinal Studies, COCONEL cohort surveys, Covid-19, Pandemics, Aged
Abstract: Background In view of experts’ warnings about the potential negative mental health consequences of the sudden nationwide lockdowns implemented in many countries to limit the spread of the COVID-19 pandemic, we sought to study the incidence of posttraumatic stress disorder (PTSD) after traumatic events related to this unprecedented lockdown in the French general population. Methods This longitudinal study among adults (aged =18) consisted of two surveys: the first during the last days of the lockdown and the second a month later. We estimated PTSD incidence with the PCL-5 and ran multiple Poisson regression models to identify factors associated with PTSD. Results Among the 1736 participants, 30.1% reported at least one traumatic event. PTSD incidence was 17.5% (95% confidence interval CI = 15.7–19.3). It was higher in participants who reported multiple traumatic events, who had high COVID-19-related media use, who had general anxiety disorder (GAD-7) during the lockdown, and who had GAD, depression (PHQ-9), or sleep problems 1 month later. In addition, 43.1% of people with PTSD reported suicidal thoughts. Conclusions These results should help clinicians to target people who are at high risk of developing PTSD after a pandemic-related lockdown and could benefit from preventive measures. Collaboration between the media and mental health professionals could be envisioned to inform the population about care resources. Follow-up recommendations should also be disseminated to general practitioners to facilitate PTSD screening and ensure that they are aware of the appropriate management.
Published: 2022

7. Additional file 1 of Incidence of PTSD in the French population a month after the COVID-19 pandemic-related lockdown: evidence from a national longitudinal survey

Author: Alleaume, Caroline, Peretti-Watel, Patrick, Beck, François, Leger, Damien, Vaiva, Guillaume, and Verger, Pierre
Abstract: Additional file 1: Figure 1. Time that the event was reported, during the lockdown (first survey) or/and one month later (second survey), and incidence of PTSD. Table 1. PTSD score according to population characteristics among those who experienced a traumatic event during the lockdown (COCONEL 2020, N = 1046).
Published: 2022
Full Text: View/download PDF

8. Vignettes from The shallow of your smile: the ethics of expressive vocal deep-fakes

Author: Guerouaou, Nadia, Vaiva, Guillaume, and Aucouturier, Jean-Julien
Abstract: original french version and english translation of the vignettes used in the study
Published: 2021
Full Text: View/download PDF

9. sj-docx-1-anp-10.1177_00048674211043455 – Supplemental material for Suicide mortality after a nonfatal suicide attempt: A systematic review and meta-analysis

Author: Demesmaeker, Alice, Chazard, Emmanuel, Hoang, Aline, Vaiva, Guillaume, and Amad, Ali
Subjects: FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), Neuroscience
Abstract: Supplemental material, sj-docx-1-anp-10.1177_00048674211043455 for Suicide mortality after a nonfatal suicide attempt: A systematic review and meta-analysis by Alice Demesmaeker, Emmanuel Chazard, Aline Hoang, Guillaume Vaiva and Ali Amad in Australian & New Zealand Journal of Psychiatry
Published: 2021
Full Text: View/download PDF

10. sj-docx-2-anp-10.1177_00048674211043455 – Supplemental material for Suicide mortality after a nonfatal suicide attempt: A systematic review and meta-analysis

Author: Demesmaeker, Alice, Chazard, Emmanuel, Hoang, Aline, Vaiva, Guillaume, and Amad, Ali
Subjects: FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), Neuroscience
Abstract: Supplemental material, sj-docx-2-anp-10.1177_00048674211043455 for Suicide mortality after a nonfatal suicide attempt: A systematic review and meta-analysis by Alice Demesmaeker, Emmanuel Chazard, Aline Hoang, Guillaume Vaiva and Ali Amad in Australian & New Zealand Journal of Psychiatry
Published: 2021
Full Text: View/download PDF

11. Religiosity and prevalence of suicide, psychiatric disorders and psychotic symptoms in the French general population Running title: Religiosity and psychiatric disorders

Author: Brito, Maria Alice, Amad, Ali, Rolland, Benjamin, Geoffroy, Pierre, Peyre, Hugo, Roelandt, Jean-Luc, Benradia, Imane, Thomas, Pierre, Vaiva, Guillaume, Schürhoff, Franck, Pignon, Baptiste, Université de Paris (UP), Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Robert Debré, Etablissements Public de Santé [Lille-Métropole] (EPSM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris Cité (UPCité), Lille Neurosciences & Cognition - U 1172 (LilNCog), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Pignon, Baptiste
Subjects: Psychotic disorders, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Mood disorders, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Religious beliefs, Religious observance, Suicide attempts
Abstract: International audience; We aimed to examine the association between religious beliefs and observance and the prevalence of psychiatric disorders, psychotic symptoms and history of suicide attempts in the French general population. The cross-sectional survey interviewed 38,694 subjects between 1999 and 2003, using the MINI. Current religious beliefs and observance were identified by means of two questions: “are you a believer?” and “are you religiously observant?”. We studied the association between religiosity and psychiatric outcomes using a multivariable logistic regression model adjusted for sociodemographic characteristics, including migrant status. Religious beliefs were positively associated with psychotic symptoms and disorders [OR = 1.37, 95% CI (1.30–1.45) and OR = 1.38, 95% CI (1.20–1.58)], unipolar depressive disorder [OR = 1.15, 95% CI (1.06–1.23)] and generalized anxiety disorder [OR = 1.13, 95% CI (1.06–1.21)], but negatively associated with bipolar disorder [OR = 0.83, 95% CI (0.69–0.98)], alcohol use disorders [OR = 0.69, 95% CI (0.62–0.77)], substance use disorders [OR = 0.60, 95% CI (0.52–0.69)] and suicide attempts [OR = 0.90, 95% CI (0.82–0.99)]. Religious observance was positively associated with psychotic symptoms and disorders [OR = 1.38, 95% CI (1.20–1.58) and OR = 1.25, 95% CI (1.07–1.45)], but negatively associated with social anxiety disorder [OR = 0.87, 95% CI (0.76–0.99)], alcohol use disorders [OR = 0.60, 95% CI (0.51–0.70)], substance use disorders [OR = 0.48, 95% CI (0.38–0.60)] and suicide attempts [OR = 0.80, 95% CI (0.70–0.90)]. Among believers, religious observance was not associated with psychotic outcomes. Religiosity appears to be a complex and bidirectional determinant of psychiatric symptoms and disorders. In this respect, religiosity should be more thoroughly assessed in epidemiological psychiatric studies, as well as in clinical practice.
Published: 2021

12. sj-docx-2-anp-10.1177_00048674211043455 – Supplemental material for Suicide mortality after a nonfatal suicide attempt: A systematic review and meta-analysis

Author: Demesmaeker, Alice, Chazard, Emmanuel, Hoang, Aline, Vaiva, Guillaume, and Amad, Ali
Subjects: FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), Neuroscience
Abstract: Supplemental material, sj-docx-2-anp-10.1177_00048674211043455 for Suicide mortality after a nonfatal suicide attempt: A systematic review and meta-analysis by Alice Demesmaeker, Emmanuel Chazard, Aline Hoang, Guillaume Vaiva and Ali Amad in Australian & New Zealand Journal of Psychiatry
Published: 2021
Full Text: View/download PDF

13. cover story from The shallow of your smile: the ethics of expressive vocal deep-fakes

Author: Guerouaou, Nadia, Vaiva, Guillaume, and Aucouturier, Jean-Julien
Abstract: original french version of the cover story used in the study
Published: 2021
Full Text: View/download PDF

14. A Digital Companion, the Emma App, for Ecological Momentary Assessment and Prevention of Suicide: Quantitative Case Series Study

Author: Morgiève, Margot, Genty, Catherine, Azé, Jérôme, Dubois, Jonathan, Leboyer, Marion, Vaiva, Guillaume, Berrouiguet, Sofian, Courtet, Philippe, Hôpital Lapeyronie [Montpellier] (CHU), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), ADVanced Analytics for data SciencE (ADVANSE), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier (LIRMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hôpital Albert Chenevier, Fondation FondaMental [Créteil], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale (SPURBO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale (EA7479 SPURBO), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), and École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)-IMT Atlantique (IMT Atlantique)
Subjects: Suicide Prevention, Original Paper, Ecological Momentary Assessment, Mental Disorders, prediction, Information technology, T58.5-58.64, Mobile Applications, [INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG], prevention, mHealth, Surveys and Questionnaires, case reports, Humans, Public aspects of medicine, RA1-1270, mobile health, suicide, ecological momentary intervention
Abstract: BackgroundMany suicide risk factors have been identified, but traditional clinical methods do not allow for the accurate prediction of suicide behaviors. To face this challenge, emma, an app for ecological momentary assessment (EMA), ecological momentary intervention (EMI), and prediction of suicide risk in high-risk patients, was developed. ObjectiveThe aim of this case report study was to describe how subjects at high risk of suicide use the emma app in real-world conditions. MethodsThe Ecological Mental Momentary Assessment (EMMA) study is an ongoing, longitudinal, interventional, multicenter trial in which patients at high risk for suicide are recruited to test emma, an app designed to be used as a self-help tool for suicidal crisis management. Participants undergo clinical assessment at months 0, 1, 3, and 6 after inclusion, mainly to assess and characterize the presence of mental disorders and suicidal thoughts and behaviors. Patient recruitment is still ongoing. Some data from the first 14 participants who already completed the 6-month follow-up were selected for this case report study, which evaluated the following: (1) data collected by emma (ie, responses to EMAs), (2) metadata on emma use, (3) clinical data, and (4) qualitative assessment of the participants' experiences. ResultsEMA completion rates were extremely heterogeneous with a sharp decrease over time. The completion rates of the weekly EMAs (25%-87%) were higher than those of the daily EMAs (0%-53%). Most patients (10/14, 71%) answered the EMA questionnaires spontaneously. Similarly, the use of the Safety Plan Modules was very heterogeneous (2-75 times). Specifically, 11 patients out of 14 (79%) used the Call Module (1-29 times), which was designed by our team to help them get in touch with health care professionals and/or relatives during a crisis. The diversity of patient profiles and use of the EMA and EMI modules proposed by emma were highlighted by three case reports. ConclusionsThese preliminary results indicate that patients have different clinical and digital profiles and needs that require a highly scalable, interactive, and customizable app. They also suggest that it is possible and acceptable to collect longitudinal, fine-grained, contextualized data (ie, EMA) and to offer personalized intervention (ie, EMI) in real time to people at high risk of suicide. To become a complementary tool for suicide prevention, emma should be integrated into existing emergency procedures. Trial RegistrationClinicalTrials.gov NCT03410381; https://clinicaltrials.gov/ct2/show/NCT03410381
Published: 2020

15. Additional file 1 of The PRINTEMPS study: protocol of a cluster-randomized controlled trial of the local promotion of a smartphone application and associated website for the prevention of suicidal behaviors in the adult general population in France

Author: Gandré, Coralie, Jeannic, Anaïs Le, Marie-Amélie Vinet, Turmaine, Kathleen, Courtet, Philippe, Roelandt, Jean-Luc, Vaiva, Guillaume, Giraudeau, Bruno, Alberti, Corinne, and Chevreul, Karine
Subjects: education, Data_FILES, food and beverages, behavioral disciplines and activities, humanities
Abstract: Additional file 1. Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist.
Published: 2020
Full Text: View/download PDF

16. Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Author: Godin, Ophelia, Bennabi, Djamila, Yrondi, Antoine, Richieri, Raphaëlle, D’amato, Thierry, Bellivier, Franck, Bougerol, Thierry, Horn, Mathilde, Camus, Vincent, Courtet, Philippe, Doumy, Olivier, Genty, Jean Baptiste, El-Hage, Wissam, Haesebaert, Frédéric, Holtzmann, Jérôme, Lançon, Christophe, Leboyer, Marion, Llorca, Pierre Michel, Maruani, Julia, Moliere, Fanny, Samalin, Ludovic, Schmitt, Laurent, Stéphan, Florian, Vaiva, Guillaume, Walter, Michel, Aouizerate, Bruno, Haffen, Emmanuel, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fondation FondaMental [Créteil], Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Hospitalier le Vinatier [Bron], Neurobiologie et Psychiatrie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), CHU Toulouse [Toulouse], Hopital de Bohars - CHRU Brest (CHU - BREST ), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Charles Perrens, Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Centre hospitalier Charles Perrens [Bordeaux]
Subjects: [SCCO]Cognitive science, Prevalence of metabolic syndrome (MetS), [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Treatment-resistant depression (TRD)
Abstract: International audience; BACKGROUND:The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) and its components in a cohort of French patients with treatment-resistant depression (TRD) and to determine correlations with sociodemographic, clinical, and treatment-related factors.METHODS:From 2012 to 2018, 205 patients who met DSM-IV criteria for major depressive episode with moderate-to-severe symptoms (Montgomery-Asberg Depression Rating Scale score ≥ 20), and at least Stage II resistance according to Thase and Rush criteria were enrolled in the FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) cohort. Data on sociodemographic and clinical characteristics, lifestyle information, and treatment and comorbidities were collected, and a blood sample was drawn. MetS was defined according to the criteria of the International Diabetes Federation.RESULTS:Overall, 38% of individuals with TRD met criteria for MetS. The frequency of MetS was significantly higher in men than in women only for patients aged 40 years or older (46.3% vs 35.2%, P = .0427). Moreover, whereas the management for diabetes was good, less than one-third of the patients with high blood pressure or dyslipidemia were treated for these conditions. Multivariate analysis showed that individuals with abnormal plasma c-reactive protein levels had a 3-fold increased risk (95% CI, 1.5-5.2) of having MetS, independent of other potential confounders.CONCLUSION:The prevalence of MetS is higher in patients with TRD than in those with other psychiatric disorders and characterized by a considerable undertreatment of some components of MetS in this population. Diagnosis and treatment of the components of MetS should be systematically performed to prevent the occurrence of cardiovascular diseases in patients with TRD. These findings highlight the need for integrated care, with more interaction and coordination between psychiatrists and primary care providers.
Published: 2019

17. Combining Postcards, Crisis Cards, and Telephone Contact Into a Decision-Making Algorithm to Reduce Suicide Reattempt

Author: Vaiva, Guillaume, Berrouiguet, Sofian, Walter, Michel, Courtet, Philippe, Ducrocq, François, Jardon, Vincent, Larsen, Mark, Cailhol, Lionel, Godesense, Carole, Couturier, Christophe, Mathur, Anjali, Lagree, Virginie, Pichene, Catherine, Travers, David, Lemogne, Cédric, Henry, Jean Marc, Jover, Frederic, Chastang, Francoise, Prudhomme, Olivier, Lestavel, Philippe, Gignac, Catherine Thevenon, Duhem, Stéphane, Demarty, Anne Laure, Mesmeur, Catherine, Bellivier, Frank, Labreuche, Julien, Duhamel, Alain, Goldstein, Patrick, Service de Psychiatrie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Michel Fontan 1, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), CHRU Brest - Psychiatrie Adulte (CHU - Brest- Psychiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Samu du Nord–pôle de l’urgence [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier de Montauban, Centre Hospitalier de Roubaix, Centre Hospitalier de Dunkerque, CHU Toulouse [Toulouse], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Psychiatrie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Hospitalier Universitaire de Nice (CHU Nice), Service de psychiatrie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier [Douai, Nord], Centre Hospitalier de Tourcoing, Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 (CIC Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), CIC Lille, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Santé publique : épidémiologie et qualité des soins-EA 2694 (CERIM), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Centre hospitalier de Montauban (CH Montauban), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes (UR)-CHU Pontchaillou [Rennes], and Centre de Psychiatrie et Neurosciences (U894)
Subjects: [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health
Abstract: International audience; BACKGROUND:There is growing evidence in the literature that brief contact interventions (BCIs) might be reliable suicide prevention strategies.OBJECTIVE:To assess the effectiveness of a decision-making algorithm for suicide prevention (ALGOS) combining existing BCIs in reducing suicide reattempts in patients discharged after a suicide attempt.METHODS:A randomized, multicenter, controlled, parallel trial was conducted in 23 hospitals. The study was conducted from January 26, 2010, to February 28, 2013. People who had made a suicide attempt were randomly assigned to either the intervention group (ALGOS) or the control group. The primary outcome was the rate of participants who reattempted suicide (fatal or not) within the 6-month study period.RESULTS:1,040 patients were recruited. After 6 months, 58 participants in the intervention group (12.8%) reattempted suicide compared with 77 (17.2%) in the control group. The difference between groups (4.4%; 95% CI, -0.7% to 9.0%) was not significant (complete-case analysis, P = .059).CONCLUSIONS:These results may help researchers better integrate BCIs into routine health care and provide new insights concerning personalized suicide prevention strategies.TRIAL REGISTRATION:ClinicalTrials.gov identifier: NCT01123174.
Published: 2018

18. Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental)

Author: Yrondi, Antoine, Bennabi, Djamila, Haffen, Emmanuel, Garnier, Marion, Bellivier, Frank, Bourgerol, Thierry, Camus, Vincent, D'Amato, Thierry, Doumy, Olivier, Haesebaert, Frédéric, Holtzmann, Jérôme, Lançon, Christophe, Vignaud, Philippe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaelle, Domenech, Philippe, Rabu, Corentin, Mallet, Luc, Yon, Liova, Schmitt, Laurent, Stephan, Florian, Vaiva, Guillaume, Walter, Michel, Llorca, Pierre-Michel, Courtet, Philippe, Leboyer, Marion, El-Hage, Wissam, Aouizerate, Bruno, Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation FondaMental [Créteil], Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Département de neurosciences (CHU Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor, Oxalya, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service Psychiatrie et psychologie médicale [CHU Purpan], CHU Toulouse [Toulouse], Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Ethique, Professionalisme et Santé (JE 2535-EPS), Université de Brest (UBO)-Institut des Sciences de l'Homme et de la Société - ISHS, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Science et Technologie du Lait et de l'Oeuf (STLO), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Clermont-Ferrand, Centre Hospitalier Universitaire [Grenoble] (CHU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier le Vinatier [Bron], Hôpital Charles Perrens, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Université Lumière - Lyon 2 (UL2), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Hopital de Bohars - CHRU Brest (CHU - BREST ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Hôpital Henri Mondor, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de psychiatrie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Institut des Sciences Cognitives (ISC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Image, Ville, Environnement (LIVE), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), CHRU Brest - Psychiatrie Adulte (CHU - Brest- Psychiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-CHU Clermont-Ferrand, Fondation Fondamental, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre hospitalier Charles Perrens [Bordeaux], Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Neurologie et thérapeutique expérimentale, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), El-Hage, Wissam, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, Département de neurosciences ( CHU Henri Mondor ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière ( CRICM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Lumière - Lyon 2 ( UL2 ), Laboratoire de Neurosciences de Brest ( LNB ), Université de Brest ( UBO ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), Ethique, Professionalisme et Santé ( JE 2535-EPS ), Université de Brest ( UBO ) -Institut des Sciences de l'Homme et de la Société - ISHS, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, CHRU Tours, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, UMR U 1253, Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], UMR 7362, Laboratoire Image, Ville, Environnement [Strasbourg] (LIVE), Université de Strasbourg (UNISTRA)-Université de Strasbourg (UNISTRA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Douhairie, Marie-Laurence, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), and Guedj, Eric
Subjects: lcsh:RC435-571, assessment, [SDV]Life Sciences [q-bio], [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, depressive disorder, lcsh:Psychiatry, Clinical Study Protocol, ComputingMilieux_MISCELLANEOUS, Psychiatry, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, innovative strategies, [SDV] Life Sciences [q-bio], [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [ SCCO.NEUR ] Cognitive science/Neuroscience, treatment-resistant depression, network, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background Major depression is characterized by (i) a high lifetime prevalence of 16–17% in the general population; (ii) a high frequency of treatment resistance in around 20–30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs. In this context, there is an important need for the development of a network of expert centers for treatment-resistant depression (TRD), as performed under the leadership of the Fondation FondaMental. Methods The principal mission of this national network is to establish a genuine prevention, screening, and diagnosis policy for TRD to offer a systematic, comprehensive, longitudinal, and multidimensional evaluation of cases. A shared electronic medical file is used referring to a common exhaustive and standardized set of assessment tools exploring psychiatric, non-psychiatric, metabolic, biological, and cognitive dimensions of TRD. This is paralleled by a medico-economic evaluation to examine the global economic burden of the disease and related health-care resource utilization. In addition, an integrated biobank has been built by the collection of serum and DNA samples for the measurement of several biomarkers that could further be associated with the treatment resistance in the recruited depressed patients. A French observational long-term follow-up cohort study is currently in progress enabling the extensive assessment of resistant depressed patients. In those unresponsive cases, each expert center proposes relevant therapeutic options that are classically aligned to the international guidelines referring to recognized scientific societies. Discussion This approach is expected to improve the overall clinical assessments and to provide evidence-based information to those clinicians most closely involved in the management of TRD thereby facilitating treatment decisions and choice in everyday clinical practice. This could contribute to significantly improve the poor prognosis, the relapsing course, daily functioning and heavy burden of TRD. Moreover, the newly created French network of expert centers for TRD will be particularly helpful for a better characterization of sociodemographic, clinical, neuropsychological, and biological markers of treatment resistance required for the further development of personalized therapeutic strategies in TRD.
Published: 2017

19. Why media coverage of suicide may increase suicide rates? An epistemological review

Author: Notredame, Charles-Edouard, Pauwels, Nathalie, Walter, Michel, Danel, Thierry, Nandrino, Jean-Louis, Vaiva, Guillaume, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Niederkrotenthaler, Thomas, Stack, Steven, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, and Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab)
Subjects: [SCCO]Cognitive science
Published: 2017

20. La dermatillomanie, un trouble à connaitre en psychiatrie : Revue de la littérature à propos d’un cas

Author: Bahri, K., Servant, Dominique, Vaiva, Guillaume, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: [SCCO]Cognitive science
Published: 2017

21. Interest of computer-based cognitive behavioral stress management. Feasability of the Seren@ctif program

Author: Servant, Dominique, Rougegrez, Laure, Barasino, Olivia, Demarty, Anne-Laure, Duhamel, Alain, Vaiva, Guillaume, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Service de Psychiatrie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Michel Fontan 1, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: Adult, Male, Psychiatric Status Rating Scales, Psychotropic Drugs, Cognitive Behavioral Therapy, Anxiety, Middle Aged, Adjustment Disorders, [SCCO]Cognitive science, Treatment Outcome, Patient Education as Topic, Patient Satisfaction, Therapy, Computer-Assisted, Feasibility Studies, Humans, Female, Software, Stress, Psychological, Aged
Abstract: INTRODUCTION: Cognitive-behavioural stress management programs have been studied in many countries. Many reports have shown beyond a doubt their efficacy to reduce perceived stress, anxiety symptoms and to improve quality of life of patients. Considering the very large number of people who could benefit from such programs but are unable to reach them, self-help programs have been offered. First presented as books (bibliotherapy), these programs then became enriched by computing and digital supports. Regrettably, many of the programs of stress management based on the Cognitive behavioural therapy (CBT) both in face-to-face and on digital support have been little evaluated in France. To our knowledge, the Seren@ctif program is the first French language self-help program of stress management proposed on digital support. AIM OF THE STUDY: We led a feasibility study of this program on 10 patients responding to the diagnosis of adjustment disorder with anxiety according to the DSM IV criteria. METHODS: The program includes 5 weekly sessions that the patient follows in our unit from a web site. He benefits from minimal contact with a medical member of staff before and after every session. Right from the first session an USB key is supplied to the patient containing videos, audio files, self-help book portfolio in the form of an e-guide, and log books with the exercises to be realized between each sessions of the 5 session program. The patient is encouraged to practice 20 minutes of exercises 5 or 6 days per week. The program's feasibility has been assessed in accordance with a standard satisfaction scale. Anxiety symptomatology has been quantified thanks to the Spielberger State-Trait Anxiety Inventory (STAI-Y-S). RESULTS: After the scheduled 5 weeks, good results were found in terms of acceptability and attractiveness. The average score to the satisfaction survey was at least equal to 4 out of 5 for each item. The mean score on the STAI-State decreased from 53,4 (SD: 8,29) to 44,2 (SD: 7,73) following the intervention. DISCUSSION: The Seren@ctif program may be useful within the framework of a psychoeducative approach. It could also be advised for people suffering from anxiety related to stress. Soon, the program will be tested on patients with usual care suffering from adjustment disorder with anxiety in order to precisely assess its benefits.
Published: 2016

22. Dépression résistante : les autres stratégies thérapeutiques

Author: Saba, Ghassen, Nieto, Isabel, Bation, Rémy, Allaïli, Najib, Bennabi, Djamila, Moliere, Fanny, Richieri, Raphaëlle, Holtzmann, Jérôme, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courtet, Philippe, Courvoisier, Pierre, Haesebaert, Frédéric, Doumy, Olivier, El-Hage, Wissam, Garnier, Marion, D'Amato, Thierry, Bougerol, Thierry, Lançon, Christophe, Haffen, Emmanuel, Llorca, Pierre-Michel, Vaiva, Guillaume, Bellivier, Frank, Leboyer, Marion, Aouizerate, Bruno, Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Fondation FondaMental [Créteil], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier le Vinatier [Bron], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Pôle Psychiatrie et Neurologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service de Psychiatrie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Michel Fontan 1, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Clermont-Ferrand, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Charles Perrens, and Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Depressive Disorder, S-Adenosylmethionine, Monoamine Oxidase Inhibitors, Drug Resistance, Antidepressive Agents, Food-Drug Interactions, Folic Acid, Double-Blind Method, Dietary Supplements, Dopamine Agonists, Fatty Acids, Omega-3, Humans, Central Nervous System Stimulants, Drug Interactions, Drug Therapy, Combination, Ketamine, Adrenergic alpha-Agonists, Excitatory Amino Acid Antagonists, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Randomized Controlled Trials as Topic
Abstract: International audience; Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment.
Published: 2016

23. Resistant depression : Switching and combining strategies of ă antidepressant medications

Author: Charpeaud, Thomas, Moliere, Fanny, Bubrovszky, Maxime, Haesebaert, Frederic, Allaïli, Najib, Bation, Remy, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Bellivier, Frank, Bennabi, Djamila, Holtzmann, Jerome, Camus, Vincent, Courtet, Philippe, Courvoisier, Pierre, d'Amato, Thierry, Doumy, Olivier, Garnier, Marion, Bougerol, Thierry, Lançon, Christophe, Haffen, Emmanuel, Leboyer, Marion, Llorca, Pierre-Michel, Vaiva, Guillaume, El-Hage, Wissam, Aouizerate, Bruno, Fondation FondaMental [Créteil], CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre de neuroImagerie de Recherche, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, INSERM U955, équipe 15, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Vulnérabilité à la schizophrénie : des bases neurobiologiques à la thérapeutique, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR19-Centre Hospitalier le Vinatier [Bron], Clinique Universitaire de Psychiatrie, CHU Grenoble, Service de Psychiatrie, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Interdisciplinary Institute for Neuroscience (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Service de psychiatrie adulte - B, Pôle de Psychiatrie, Faculté de Médecine-IFR10-Groupe hospitalier Henri Mondor-Albert Chenevier, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Charles Perrens, CHU Gabriel Montpied [Clermont-Ferrand], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation Fondamental, CHU Gabriel Montpied ( CHU ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Variabilité de réponse aux psychotropes ( VariaPsy - U1144 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Diderot - Paris 7 ( UPD7 ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Fondation FondaMental, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Interdisciplinaire de Neurosciences ( IINS ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), CHRU Tours, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre hospitalier Charles Perrens [Bordeaux], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP], Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: [ SHS.PSY ] Humanities and Social Sciences/Psychology, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Quality of Life, [ SHS.ECO ] Humanities and Social Sciences/Economies and finances, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Abstract: International audience; Switching antidepressant medication may be helpful in depressed patients ă having no benefit from the initial antidepressant treatment. ă Before considering switching strategy, the initial antidepressant ă treatment should produce no therapeutic effect after at least 4 weeks of ă administration at adequate dosage. ă Choosing an antidepressant of pharmacologically distinct profile fails ă to consistently demonstrate a significant superiority in terms of ă effectiveness over the switching to another antidepressant within the ă same pharmacological class. ă Augmenting SSRI/SNRIs with mirtazapine/mianserin has become the most ă recommended strategy of antidepressant combinations. ă Augmenting SSRI with tricyclic drugs is now a less recommended strategy ă of antidepressant combinations given the increased risk for the ă occurrence of pharmacokinetic drug-drug interactions and adverse ă effects.
Published: 2016

24. Resistant depression : potentiation strategies

Author: Doumy, Olivier, Bennabi, Djamila, El-Hage, Wissam, Allaïli, Najib, Bation, Remy, Bellivier, Frank, Holtzmann, Jerome, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courvoisier, Pierre, D'Amato, Thierry, Garnier, Marion, Haesebaert, Frederic, Bougerol, Thierry, Lançon, Christophe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Courtet, Philippe, Vaiva, Guillaume, Leboyer, Marion, Llorca, Pierre-Michel, Aouizerate, Bruno, Haffen, Emmanuel, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de neuroImagerie de Recherche, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Fondation FondaMental [Créteil], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Vulnérabilité à la schizophrénie : des bases neurobiologiques à la thérapeutique, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR19-Centre Hospitalier le Vinatier [Bron], Clinique Universitaire de Psychiatrie, CHU Grenoble, Service de Psychiatrie, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, INSERM U955, équipe 15, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Pôle de Psychiatrie, Faculté de Médecine-IFR10-Groupe hospitalier Henri Mondor-Albert Chenevier, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Interdisciplinary Institute for Neuroscience (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Service de psychiatrie adulte - B, Centre hospitalier Charles Perrens [Bordeaux], Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), CHU Gabriel Montpied (CHU), Université Grenoble Alpes (UGA), Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Neuropsychiatrie : recherche épidémiologique et clinique, Hôpital Charles Perrens, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHRU Tours, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP], Variabilité de réponse aux psychotropes ( VariaPsy - U1144 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Fondation Fondamental, CHU Gabriel Montpied ( CHU ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 ( UCBL ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Fondation FondaMental, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Interdisciplinaire de Neurosciences ( IINS ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Diderot - Paris 7 ( UPD7 ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, and Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)
Subjects: [ SHS.PSY ] Humanities and Social Sciences/Psychology, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Quality of Life, [ SHS.ECO ] Humanities and Social Sciences/Economies and finances, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Abstract: International audience; Lithium is among the most classically recommended add-on therapeutic ă strategy for the management of depressive patients showing unsuccessful ă response to standard antidepressant medications. ă The effectiveness of the add-on strategy with lithium requires achieving ă plasma levels above 0.5 mEq/L. ă Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate ă derivatives or lamotrigine have not demonstrated conclusive therapeutic ă effects for the management of depressive patients showing unsuccessful ă response to standard antidepressant medications. ă Thyroid hormones are considered among the currently recommended add-on ă therapeutic strategy for the management of depressive patients showing ă unsuccessful response to standard antidepressant medications. ă The effectiveness of the add-on strategy with thyroid hormones requires ă achieving plasma concentration of TSH close to the lower limits at the ă normal range (0.4 mUI/L) or even below it. Second-generation ă antipsychotics such as aripiprazole or quetiapine have consistently ă demonstrated significant therapeutic effects for the management of ă depressive patients showing unsuccessful response to standard ă antidepressant medications. ă Second-generation antipsychotics however require the careful monitoring ă of both cardiovascular and metabolic adverse effects.
Published: 2016

25. [Prevalence of psychiatric and substance use disorders among three generations of migrants: Results from French population cohort]

Author: Guardia, Dewi, Salleron, Julia, Roelandt, Jean-Luc, Vaiva, Guillaume, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Collaborateur de l'Organisation Mondiale de la Santé pour la recherche et la formation en santé mentale (CC-OMS), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: Adult, Aged, 80 and over, Male, Transients and Migrants, Family Characteristics, Adolescent, Substance-Related Disorders, Mental Disorders, Middle Aged, Cohort Studies, [SCCO]Cognitive science, Young Adult, Prevalence, Humans, Family, Female, France, Aged
Abstract: INTRODUCTION: Mental health of migrant populations has become a major public health issue since these populations more often suffer from mental health problems than host populations. The influence of the migration process on the emergence of these disorders and its impact on future generations is uncertain. This study provides an estimate of the prevalence of mental disorders among three generations of migration. METHOD: The study was conducted in the general population by the French Collaborating Center of the World Health Organization, in France, on a sample of 37,063 people aged 18 and older. The subjects interviewed were selected by a quota sampling method and, thus, were representative of the general population in the 47 study sites in France. This method develops a sample of subjects with the same characteristics as the general population on predefined issues, such as age, sex, educational level and socioprofessional category. The designation of migrant status was based on the country of birth of the subject, the subject's parents and the subject's grandparents. We defined a migrant as first generation (a subject born abroad; n=1911), second generation (at least one parent born abroad; n=4147), or third generation (at least one grandparent born abroad; n=3763) of migrants. The diagnostic tool used was the Mini International Neuropsychiatric Interview (MINI). The MINI is a brief structured diagnostic interview developed by psychiatrists for ICD-10 and DSM-IVTR psychiatric disorders in the general population. The comparisons by generation of migrants were performed by chi-square test for qualitative variables and by an analysis of variance for quantitative variables. The same tests were used to compare the presence of mental disorders according to the characteristics of the population. Factors with a P-value less than 0.2 were entered in a multivariable logistic regression to assess the relationship between the generation of migrants and the presence of mental disorders, adjusting for the confounding factors. RESULTS: Thirty-eight per cent of migrant subjects have psychological difficulties, versus 30 % in the host population. These results are observed on three successive generations of migrants. Migration status increases risk of depressive disorders (OR=1.555), bipolar disorder (OR=1.597, CI=1.146-2.227), post-traumatic stress disorder (OR=1.615), substance abuse (OR=2.522) and alcohol abuse (OR=1.524), and drug dependence (OR=2.116). This risk is maintained at the second and third generation. The migration process affects mental health of population regardless of socioeconomic status or geographic origin. CONCLUSION: The consideration of migration and generation of migration shows a specific psychopathological risk profile. This is related to the joint action of a migratory past and precarious socioeconomic situation.
Published: 2016

26. Depression et stress post-traumatique

Author: Warembourg, Frédérique, Ducrocq, François, Vaiva, Guillaume, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Haffen, E., and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: [SCCO]Cognitive science
Published: 2016

27. Media coverage of suicide: From the epidemiological observations to prevention avenues

Author: Notredame, Charles-Edouard, Pauwels, Nathalie, Walter, Michel, Danel, Thierry, Vaiva, Guillaume, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Hopital de Bohars - CHRU Brest (CHU - BREST ), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: Suicide Prevention, Suicide, [SCCO]Cognitive science, Cross-Sectional Studies, Risk Factors, Statistics as Topic, Humans, Mass Media, Imitative Behavior
Abstract: Media coverage of suicide can result in increased morbi-mortality suicidal rates, due to an imitation process in those who are particularly vulnerable. This phenomenon is known as "Werther effect". Werther effect's magnitude depends on several qualitative and quantitative characteristics of the media coverage, in a dose-effect relationship. An extensive (in terms of audience and history repetition) and salient coverage (glorification of suicide, description of the suicidal method, etc.) increases the risk of contagion. Celebrities' suicide is particularly at risk of Werther effect. Media may also have a preventive role with respect to suicide. Indeed, according to "Papageno effect", journalists could, under certain conditions, help preventing suicide when reporting suicide stories. Two main theories in the field of social psychology have been proposed to account for Werther and Papageno effects: social learning theory and differential identification. Identification of Werther and Papageno effects uncovers new responsibilities and potentialities for the journalists in terms of public health. Their description provides a basis for promising targeted prevention actions.; La couverture médiatique du suicide est associée à un risque d’augmentation de la morbi-mortalité suicidaire par effet d’incitation chez les personnes vulnérables : il s’agit de l’effet Werther.L’importance de l’effet Werther dépend des caractéristiques qualitatives et quantitatives du traitement médiatique, dans une relation dose-effet. Le risque est ainsi majoré si la couverture est abondante (en termes d’audience du média et de récurrence du fait divers) et saillante (romantisation du suicide, description du moyen suicidaire…).Le suicide des célébrités est particulièrement à risque d’effet Werther.Les médias auraient également un potentiel préventif quant au suicide. L’effet Papageno prédit que le traitement journalistique du suicide pourrait, sous certaines conditions, contribuer à prévenir certains passages à l’acte.Deux principales théories de psychologie sociale ont été proposées pour rendre compte des effets Werther et Papageno : la théorie de l’apprentissage social et la théorie de l’identification différentielle.L’identification des effets Werther et Papageno dévoile, de facto, des responsabilités et des potentialités nouvelles pour les journalistes en matière de santé publique. La caractérisation de ces effets permet de fonder des actions de prévention ciblées prometteuses.
Published: 2015

28. [Can we consider the journalist an actor in suicide prevention?]

Author: Notredame, Charles-Edouard, Pauwels, N., Vaiva, Guillaume, Danel, Thierry, Walter, M., Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), and Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille
Subjects: Suicide Prevention, [SCCO]Cognitive science, Suicide, Journalism, Humans, Mass Media, Suicidal Ideation
Abstract: INTRODUCTION: After more than 50 years of dedicated research, media coverage of suicide is now well known to have a significant influence on the suicide epidemiology. This influence is supposed to result from two opposite effects. The Werther effect (WE) refers to the robust increase of suicide rates following the publication of a suicide story. This specific kind of mass cluster implies a suggestion process, i.e. imitation of the depicted death by vulnerable persons. In contract, the preventive potential of medias has been labeled the "Papageno effect" (PE). Although more recently discovered and far less known, PE predicts that journalists can help prevent suicidal behaviors beyond a simple WE reduction. Because PE and WE directly bridge journalistic productions to suicidal events, several national and international health organisms (including the World Health Organization) started to see the media as new prevention opportunities. In this paper, we intend to assess the extent to which journalists can be considered as public health actors in the specific field of suicide prevention. METHODS: Based on a critical review of the so-called Media effect studies, we explore the opportunities, limits and constraints of collaborating with media professionals for public health actions. For that purpose, we focus on the main strategy employed so far, namely providing recommendations for more cautious coverage of suicide. An overview of the efficacy of these recommendations serves not only as a starting point for understanding how public health and journalistic perspectives can confront, but also how they can be combined in a fertile way. RESULTS: Numerous suicide prevention organisms developed strategies in order to assist journalists in reporting suicide stories in a safer way. As a formal support to these strategies, around 30 national or international guides have been produced around the word, with the shared aim of reducing WE and, eventually, promoting PE. The recommendations about articles' style and content that compose these guides were shown to be similar across the countries. They mostly meet public health concerns, rest on the available knowledge about the two effects' determinants and thus advocate for a less quantitatively and qualitatively prominent coverage. However, the way the guides were produced and implemented shows considerable variations. While most countries solely edited and/or distributed the recommendations with no complementary measures, several organisms associated their publication with promotion actions towards the journalists and general public. Evidence for the impact of the guides' publication on suicide rates, although encouraging, are seriously limited by methodological considerations. As a consequence, their efficacy is more often assessed in terms of media compliance to the recommendations. The extent to which media items respect the guidelines depends considerably on the way journalists are invited - or not - to resort to them. While the strategy seems inefficient when limited to a simple publication, the quality of suicide portrayal significantly improves when the guides are part of a whole prevention campaign dealing with suicide coverage. Moreover the journalist's implication at each step of the process seems a crucial point for its success. DISCUSSION: Media professionals are submitted to their own codes, constraints and missions which do not necessarily fit with public health concerns. If considered as prescriptions to reduce the suicide rates, journalists might see recommendations for a more cautious coverage to be a threat to their independence, thus accounting for their non-compliance. On the other hand, a real collaborative approach based on shared skills and knowledge could help sensitize journalists to a responsibility that PE and WE inevitably give them. Under these conditions, recommendations can become a precious resource to help media professional when facing a sensitive issue and finally contribute to fight against suicide.
Published: 2015

29. The impact of discontinuing methylphenidate on weight and eating behavior

Author: Benard, Victoire, Cottencin, Olivier, Guardia, Dewi, Vaiva, Guillaume, Rolland, Benjamin, Service de Psychiatrie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Michel Fontan 1, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc - U837 Inserm), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille 2 - Faculté de Médecine -Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: Male, Adolescent, Mesh:Attention Deficit Disorder with Hyperactivity/drug therapy, [SDV]Life Sciences [q-bio], Mesh:Male, methylphenidate, eating disorders, amphetamines, Body Mass Index, [SCCO]Cognitive science, Mesh:Adolescent, Recurrence, mental disorders, Mesh:Weight Gain/drug effects, Humans, Central Nervous System Stimulants/therapeutic use, Mesh:Body Mass Index, Mesh:Central Nervous System Stimulants/therapeutic use, Mesh:Feeding Behavior/drug effects, attention deficit disorder with hyperactivity, Feeding Behavior/drug effects, weight gain, Feeding Behavior, Methylphenidate/therapeutic use, Mesh:Recurrence, drug toxicity, Mesh:Humans, Weight Gain/drug effects, pharmacovigilance, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity/drug therapy, Mesh:Methylphenidate/therapeutic use, human activities
Abstract: International audience; Chronic administration of the amphetamine-derivative methylphenidate (MPH) may induce appetite reduction and weight loss. By contrast, the effects that stopping chronic MPH may exert on eating behavior and body weight are poorly known. We report the case of a male patient with childhood attention deficit/hyperactivity disorder (ADHD), who discontinued MPH treatment at the age of 11 years and was lost to follow-up until the age of 16. The patient's body mass index increased by five points within 1 year of MPH cessation while the symptoms of ADHD were re-emerging. The patient secondarily developed DSM-5 criteria for eating disorders. Discontinuing chronic MPH can significantly affect weight and eating behavior. Such risks should warrant further studies, as they could be particularly increased in patients with ADHD, who share common vulnerability factors with both obesity and eating disorders.
Published: 2014

30. [Psychiatry in elderly prisoners]

Author: Fovet, Thomas, Geoffroy, Pierre-Alexis, Vaiva, Guillaume, Adins, Catherine, Thomas, Pierre, Amad, Ali, Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), and Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Subjects: Aged, 80 and over, Male, Psychiatry, Mental Disorders, Prisoners, virus diseases, social sciences, behavioral disciplines and activities, [SCCO]Cognitive science, mental disorders, population characteristics, Humans, Female, Aged
Abstract: CONTEXT: The high prevalence of psychiatric disorders in prison and the aging of inmates should lead to the consideration of gerontopsychiatry in the prison environment. OBJECTIVE: This review aims to emphasize the clinical characteristics and associated comorbidities of elderly prisoners with psychiatric disorders. We examined the international literature in September 2013 and performed the literature search with PubMed electronic database using the following Mesh headings: "prisons", "prisoners", "geriatric psychiatry", "geriatric assessment", "geriatric nursing". RESULTS: Fourteen studies were retained by the literature search strategy and were included in the qualitative analysis. More than one out of two elderly prisoners (>60 year-old) suffer from a psychiatric disorder. Major depressive disorder (MDD) is the first psychiatric disorder diagnosed among elderly prisoners, affecting 30 to 50% of them. Personality disorders are also very common demonstrating a prevalence of about 30%. Psychotic disorders concern 5% of the elderly prisoners and thus largely exceed the prevalence in the general population. Furthermore, stress events are frequent in prison and might precipitate or worsen psychiatric disorders. This review highlights the difficulties and complexities of care plans and management for the elderly in prison. CONCLUSION: The situation of elderly prisoners with psychiatric disorders is extremely worrying. In addition, both the aging of the population and the lengthening of incarcerations increase the number of elderly prisoners, widely exposed to psychiatric disorders, and thus will probably worsen these issues in the future.
Published: 2014

31. Confrontation traumatique, stress aigu, et ESPT

Author: Ducrocq, François, Vaiva, Guillaume, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Boulanger, Jean-Philippe, and Lepine, Jean-Pierre
Subjects: [SCCO]Cognitive science, ComputingMilieux_MISCELLANEOUS
Abstract: National audience
Published: 2014

32. Suivi téléphonique post-urgence des suicidants : intérêt d’un recontact téléphonique

Author: Vaiva, Guillaume, Ducrocq, François, Jehel, Louis, Duhem, Stéphane, Université de Lille, LillOA, and Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: [SCCO]Cognitive science, [SCCO] Cognitive science
Published: 2013

33. Contributeurs

Author: Adès Jean, Allilaire Jean-François, Amado Isabelle, André Christophe, Andronikof Anne, Angel Pierre, Angel Sylvie, Ansseau Marc, Bellivier Frank, Benoit Michel, Benyaya Joseph, Birmes Philippe, Boucherat-Hue Valérie, Boulenger Jean-Philippe, Bourgeois Marc-Louis, Bourguignon Aurélie, Bourin Michel, Bouvard Martine, Braconnier Alain, Brun-Eberentz Annick, Buhl Catherine, Caillard Vincent, Capdevielle Delphine, Caria Aude, Caroli François, Chagnard Éric, Charpeaud Thomas, Clément Jean-Pierre, Cohen David, Consoli Angèle, Consoli Silla, Corcos Maurice, Cordier Bernard, Paul T Costa, Coste Emmanuelle, Cottraux Jean, Courtet Philippe, Cungi Charly, Daléry Jean, Danion Jean-Marie, Darcourt Guy, Dardennes Roland, David Jean-Christophe, De Beaurepaire Christiane, De Clercq Barbara, De Fruyt Filip, Debray Quentin, Demily Caroline, Derouesné Christian, Dubertret Caroline, Dubois Anne-Marie, Duclos Jeanne, Ducrocq François, Dumas Patrick, Duprez Matthieu, Dupuy Michèle, Edel Yves, Even Christian, Falissard Bruno, Ferreri Florian, Ferreri Maurice, Foulon Christine, Franck Nicolas, Galinowski André, Gay Christian, Gérard Alain, Giraud-Baro Élisabeth, Godart Nathalie, Gorwood Philip, Goudemand Michel, Gourion David, Gueguen Bernard, Guelfi Julien-Daniel, Hanin Bertrand, Hardy Patrick, Hardy-Baylé Marie-Christine, Hermes Aziz, Ichard Karine, Jeammet Philippe, Jehel Louis, Jonas Carol, Jousselme Catherine, Kahn Jean-Pierre, Kapsambelis Vassilis, Klein Rémy, Kovess-Masfety Viviane, Krebs Marie-Odile, Lachaux Bernard, Lamas Claire, Le Bastard Guillaume, Le Moal Michel, Leguay Denis, Lejoyeux Michel, Lienard Yasmine, Limosin Frédéric, Llorca Pierre-Michel, Loas Gwénolé, Logak Zoé, Lovell Anne, Mana Stéphanie, Marcelli Daniel, Marinescu Matei, Martinot Jean-Luc, Mattar Lama, McCrae Robert, Mercuel Alain, Millet Bruno, Mirabel-Sarron Christine, Monier Claudine, Montaut Thierry, Moro Marie-Rose, Note Ivan-Druon, Olié Jean-Pierre, Paillère Marie-Laure, Pascal Jean-Charles, Pelissolo Antoine, Perdereau Fabienne, Peretti Charles-Siegfried, Petitjean François, Pham-Scottez Alexandra, Philippe Alain, Pitchot William, Poirier Marie-France, Postel Jacques, Purper-Ouakil Diane, Quellien Floran, Ramoz Nicolas, Reynaud Michel, Ritchie Karen, Robert Philippe-Henri, Rolland Jean-Pierre, Rouillon Frédéric, Roux Hélène, Ruat Annie, Schmitt Laurent, Sechter Daniel, Senon Jean-Louis, Servant Dominique, Terra Jean-Louis, Thibaut Florence, Thomas Pierre, Thurin Jean-Michel, Vaiva Guillaume, Verdoux Hélène, Vidon Gilles, Villebrun Dominique, Waintraub Lionel, Widlöcher Daniel, Wirth Nathalie, Wohl Mathias, and Xavier Jean
Published: 2012

34. Relationship between posttrauma GABA plasma levels and PTSD at 1-year follow-up

Author: Vaiva, Guillaume, Boss, Virginie, Ducrocq, François, Fontaine, Monique, Devos, Patrick, Brunet, Alain, Laffargue, Philippe, Goudemand, Michel, Thomas, Pierre, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST), Université de Franche-Comté (UFC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Technologie de Belfort-Montbeliard (UTBM), Institut Européen des membranes (IEM), Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Centre National de la Recherche Scientifique (CNRS), Stiftelsen for INdustriell og TEknisk Forskning (SINTEF), Santé publique : épidémiologie et qualité des soins-EA 2694 (CERIM), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de signalisation, biologie du développement et cancer (ISBDC), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Département de microbiologie et immunologie, Université de Montréal [Montréal], Biologie du développement et reproduction (BDR), École nationale vétérinaire d'Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS), Université du Littoral Côte d'Opale, FRE ELICO 2816 CNRS, Université du Littoral Côte d'Opale-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche sur les Ecosystèmes Littoraux Anthropisés (CRELA), Centre National de la Recherche Scientifique (CNRS)-Université de La Rochelle (ULR)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM), Stiftelsen for INdustriell og TEknisk Forskning Digital [Trondheim] (SINTEF Digital), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Université de Montréal (UdeM), Ecosystèmes littoraux et côtiers (ELICO), Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies-Université du Littoral Côte d'Opale (ULCO), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Université de La Rochelle (ULR)-Centre National de la Recherche Scientifique (CNRS), Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS), Université de Lille, Sciences et Technologies-Université du Littoral Côte d'Opale (ULCO)-Centre National de la Recherche Scientifique (CNRS), and Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-La Rochelle Université (ULR)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Traumatic, Male, MESH: Accidents, Traffic, MESH: Trauma Severity Indices, Remission, Spontaneous, MESH: gamma-Aminobutyric Acid, Cohort Studies, Stress Disorders, Post-Traumatic, 0302 clinical medicine, Longitudinal Studies, MESH: Longitudinal Studies, MESH: Cohort Studies, gamma-Aminobutyric Acid, Stress Disorders, MESH: Aged, 0303 health sciences, Trauma Severity Indices, MESH: Middle Aged, Accidents, Traffic, MESH: Stress, Psychological, MESH: Follow-Up Studies, Middle Aged, 3. Good health, Psychiatry and Mental health, MESH: Stress Disorders, Post-Traumatic, Biological Markers, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Adult, Adolescent, Remission, MESH: Depressive Disorder, Major, Acute, Stress, 03 medical and health sciences, Traffic, Humans, Stress Disorders, Traumatic, Acute, 030304 developmental biology, Aged, MESH: Adolescent, Depressive Disorder, Depressive Disorder, Major, MESH: Humans, Spontaneous, MESH: Remission, Spontaneous, MESH: Biological Markers, Major, MESH: Adult, MESH: Male, Accidents, Post-Traumatic, Psychological, MESH: Stress Disorders, Traumatic, Acute, MESH: Female, 030217 neurology & neurosurgery, Biomarkers, Stress, Psychological, Follow-Up Studies
Abstract: International audience; OBJECTIVE: Gamma-aminobutyric acid (GABA) exerts a prominent effect on central adrenergic stress responses in times of high stress and has been associated with acute posttraumatic stress disorder (PTSD). The authors examined the association between low posttrauma plasma GABA levels and long-term PTSD. METHOD: Plasma GABA levels were measured in 78 victims of road traffic accidents who met criteria for trauma exposure on arrival at a trauma department and were admitted for at least 3 days. Patients were assessed for PTSD and major depressive disorder at 6-week and 1-year follow-ups. RESULTS: At 6 weeks and at 1 year, mean posttrauma GABA levels were significantly lower among subjects who met all or nearly all criteria for PTSD than among those who did not. Among patients who met all or nearly all criteria for PTSD at 6 weeks, 75% of those with posttrauma GABA levels above 0.20 mmol/ml no longer met criteria at 1 year. By contrast, among patients whose GABA levels were below 0.20 mmol/ml, 80% met all or nearly all criteria for PTSD at 1 year. Two-thirds of patients who met all or nearly all criteria for PTSD at 1 year also met criteria for major depressive disorder. CONCLUSIONS: A plasma GABA level above 0.20 mmol/ml may protect against chronic PTSD and may represent a marker of recovery from trauma.
Published: 2006

35. [Suicide behavior in adolescents and adults]

Author: Layet, Laurent, Vaiva, Guillaume, Thomas, Pierre, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), and Wartel, Anny
Subjects: Adult, Male, Suicide Prevention, MESH: Adolescent, MESH: Age Factors, MESH: Humans, MESH: Middle Aged, Adolescent, Age Factors, Suicide, Attempted, MESH: Adult, Middle Aged, MESH: Male, Suicide, MESH: Suicide, Risk Factors, MESH: Risk Factors, MESH: Suicide, Attempted, Humans, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH: Female, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2003

36. Conduites addictives en urgence

Author: Brousse, George, Zbinden, R., Geneste, J., Cottencin, Olivier, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Vaiva, Guillaume, and Université de Lille, LillOA
Subjects: [SCCO]Cognitive science, [SCCO] Cognitive science
Published: 2014

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

36 results on '"Vaiva, Guillaume"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources